Superluminal Medicines entered a collaboration valued up to $1.3 billion with pharmaceutical leader Eli Lilly to develop small molecule therapies targeting novel G protein-coupled receptors (GPCRs) relevant to cardiometabolic diseases and obesity. Leveraging Superluminal’s AI-driven drug discovery platform integrating machine learning and structural biology, the partnership aims to address pressing global health challenges by discovering innovative treatments. The deal builds on prior investments and collaborations, aligning technological expertise with established clinical development resources.